US 10975393
Engineered target specific nucleases
granted A61KA61K38/00
Quick answer
US patent 10975393 (Engineered target specific nucleases) held by Sangamo Therapeutics, Inc. expires Mon Apr 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Sangamo Therapeutics, Inc.
- Grant date
- Tue Apr 13 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Apr 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 16
- CPC classes
- A61K, A61K38/00